St. Louis Children's Hospital

St. Louis, MO


Founded in 1879, St. Louis Children’s Hospital (SLCH) is at the forefront of pediatric medicine, providing care for children around the world. As the pediatric teaching hospital for Washington University School of Medicine (WUSM), SLCH offers nationally recognized programs for training and research. Nationally recognized as a Best Children’s Hospital by U.S. News & World Report, the 258-bed hospital includes a 36-bed pediatric intensive care unit (including a 12-bed cardiac intensive care unit), a 70-bed Level IV newborn intensive care unit and a 6-bed pediatric bone marrow transplant unit. St. Louis Children’s Hospital is a Magnet® designated hospital.

The Pediatric Neuro-Oncology Center at SLCH/WUSM offers a comprehensive, compassionate, diagnosis and treatment of pediatric tumors in the brain and spinal cord. Members of the multi-disciplinary team include pediatric neuro-oncologists, neurosurgeons, radiation oncologists, radiologists, pathologists, endocrinologists, psychologists, and other specialty staff. SLCH has access to the latest therapeutic options for children with brain tumors, including intra-operative MRI, advanced imaging modalities, and proton beam radiation therapy.

Affiliated with WUSM, the Siteman Cancer Center has an international reputation for patient care and education, as well as cancer research. The Pediatric Neuro-Oncology Program at WUSM has active basic, translational and clinical science research programs. The research programs at SLCH and WUSM benefit from a primary brain tumor-banking program that includes extensive clinical annotation of viable as well as fixed and frozen archived specimens, a high-throughput screening core for preclinical compound library screens, a genomic engineering core, cutting edge small-animal imaging facilities and a world renown genomic sciences center. Collaborative lab-based and clinical research efforts are coordinated through several monthly group meetings focused on the genomics and epigenomics, stem cell biology, experimental imaging and mechanisms of therapeutic response and resistance in pediatric brain tumors.

Housing Information

We have several free or discounted lodging options and shuttle service available to patients and their families who live more than 25 miles from St. Louis. These include Ronald McDonald House, Haven House, and many local hotels. In addition, we have several short-term leasing options at nearby apartment complexes and lofts for longer term stays. Our social worker will coordinate housing with families prior to arrival for treatment. For more information, call (314) 454-4457.

Contact information


St. Louis Children’s Hospital
One Children’s Place, 4S10
St. Louis, MO 63110

Tammy Bethel-Anderson, Neuro-Oncology Program Coordinator
Phone: (314) 454-4337
Fax: (314) 454-2737


Principal Investigator

Mohamed Abdel-Baki, MD

Dr. Mohamed Shebl Abdelbaki is the Director of the Pediatric Neuro-Oncology Program at St. Louis Children's Hospital (NCH), and an Associate Professor of Pediatrics at Washington University School of Medicine in St. Louis. He is a member of the Central Nervous System (CNS) Committee at the Children’s Oncology Group (COG), where he also serves as a study committee member for the upcoming CNS non-germinomatous germ cell tumor clinical trial (ACNS2021). Like many other Pediatric Neuro-Oncologists at large academic institutions, his responsibilities and interests include patient care, research, and education. As for patient care, he was awarded one of the highly-esteemed accolades at Nationwide Children’s Hospital (NCH) for excellence in patient care in 2016 (Partners in Care, Partners in Hope Family Centered Care Award). As far as education, he did receive the Distinguished Teaching Award from Saint Louis University School of Medicine in 2015. On the research aspect, he currently lead the early phase clinical trials for the Neuro-Oncology Program at SLCH. He is the principal investigator for several clinical trials in a variety of pediatric brain tumors. Two of his clinical trials have been approved by PNOC; the first trial will test the feasibility of administering Natural Killer (NK) cells in patients with recurrent HGGs, while the second trial (PNOC021 )was also approved by Novartis pharmaceuticals and entails testing the combination of Everolimus and Trametinib in children with recurrent low-grade gliomas.
Co-Principal Investigator
Dr. Joshua Rubin is a Pediatric Hematologist/Oncologist with nearly 20 years of clinical and lab-based experience focused on pediatric brain tumors. He is co-founder and co-Director of the Pediatric Neuro-Oncology Program at SLCH, Co-Leader of the Neuro-Oncology Focus Group at The Siteman Cancer Center and Chair of the Scientific Advisory Board for the Children’s Brain Tumor Foundation. His lab-based research interests are focused on the molecular basis for sex differences in pediatric brain tumors and novel approaches to compound library screens for preclinical drug development. His clinical research interests are in targeting the cAMP pathway for brain tumor treatment and the development of interventions for cognitive deficits in survivors of pediatric brain tumors.

Mohamed Abdel-Baki, MD